Skip to main content
SpringerLink
Log in

Focusing on cost-effective treatment in macular degeneration

  • Meeting report
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. study funded by Novartis

  2. study funded by Novartis

  3. study funded by Novartis

  4. study funded by Bayer

  5. study funded by Bayer

  6. study funded by Bayer

References

  1. De Pouvourville G, et al. A Cost-Utility Analysis of Ranibizumab in Age-Related Macular Degeneration Based on Real-Life Observational Data in France. 16th Annual European Conference of the International Society for Pharmacoeconomics and Outcomes Research : abstr. PSS33, 2 Nov 2013.

  2. Brown A, et al. Aflibercept in Neovascular (Wet) Age-Related Macular Degeneration: an Analysis of the Payer Decision Landscape. 16th Annual European Conference of the International Society for Pharmacoeconomics and Outcomes Research : abstr. PSS53, 2 Nov 2013.

  3. Haig J, et al. A Quebec Economic Evaluation for 36 Months of Ranibizumab for the Treatment of Diabetic Macular Edema. 16th Annual European Conference of the International Society for Pharmacoeconomics and Outcomes Research : abstr. PSS32, 2 Nov 2013.

  4. Clements KM, et al. Cost-Effectiveness of Intravitreal Aflibercept in Treating Neovascular Age-Related Macular Degeneration in Sweden. 16th Annual European Conference of the International Society for Pharmacoeconomics and Outcomes Research : abstr. PSS28, 2 Nov 2013.

  5. D'Ausilio A, et al. The Cost-Effectiveness of Intravitreal Aflibercept (Ivt-Afl) in Treating Neovascular Age-Related Macular Degeneration in an Italian Setting. 16th Annual European Conference of the International Society for Pharmacoeconomics and Outcomes Research : abstr. PSS21, 2 Nov 2013.

  6. Garcia-Layana A, et al. Cost-Minimization Analysis of Intravitreal Aflibercept (Ivt-Afl) for Neovascular Age-Related Macular Degeneration in Spain. 16th Annual European Conference of the International Society for Pharmacoeconomics and Outcomes Research : abstr. PSS30, 2 Nov 2013.

  7. Saxena N, et al. Cost Effectiveness of Anti-Oxidant Vitamin + Zinc Treatment to Prevent the Progression of Intermediate Age Related Macular Degeneration to its Wet Form. a Singapore Perspective. 16th Annual European Conference of the International Society for Pharmacoeconomics and Outcomes Research : abstr. PSS25, 2 Nov 2013.

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Focusing on cost-effective treatment in macular degeneration. PharmacoEcon Outcomes News 692, 5–6 (2013). https://doi.org/10.1007/s40274-013-0887-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-013-0887-3

Search

Navigation